Mabwell Receives IND Approval from FDA for Novel B7-H3 ADC 7MW3711
Mabwell's B7-H3 targeting ADC, 7MW3711, approved by FDA for advanced malignant solid tumor trials, shows promising tumor-killing effects and safety. Developed using IDDC™ platform, it features innovative components for specific tumor targeting and apoptosis induction. Mabwell, with a robust R&D system, focuses on innovative medicines across various therapeutic areas.
Reference News
Mabwell Receives IND Approval from FDA for Novel B7-H3 ADC 7MW3711
Mabwell's B7-H3 targeting ADC, 7MW3711, approved by FDA for advanced malignant solid tumor trials, shows promising tumor-killing effects and safety. Developed using IDDC™ platform, it features innovative components for specific tumor targeting and apoptosis induction. Mabwell, with a robust R&D system, focuses on innovative medicines across various therapeutic areas.